A method for enriching α-synuclein seeds from cerebrospinal fluid samples for RT-QuIC
By treating cerebrospinal fluid samples with Triton X-100 and low-concentration TCA, the problems of poor detection stability and insufficient sensitivity in RT-QuIC detection were solved, realizing rapid, sensitive and stable α-Syn detection, which is suitable for the clinical diagnosis of α-Syn-related diseases.
Patent Information
- Application Number
- CN202611316279.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-28
- Publication Date
- 2026-11-17
AI Technical Summary
Existing RT-QuIC detection technology suffers from poor detection stability, lack of standardization, and spontaneous substrate aggregation in the diagnosis of α-Syn-related diseases, resulting in false negative results and insufficient detection sensitivity, making it difficult to promote its widespread application.
Lipid-bound α-Syn seeds were dissociated using Triton X-100, and cerebrospinal fluid samples were processed using a one-step specific low-concentration TCA precipitation method, including incubation, precipitation, rinsing, and resuspension steps, to improve the enrichment efficiency and activity of α-Syn seeds.
It significantly shortens the detection time, improves detection sensitivity and stability, and solves the problem of repeatability of test results, making it suitable for clinical application.
Smart Images

Figure CN123106869A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical technology, and more specifically to a method for enriching α-synuclein seeds from cerebrospinal fluid samples for RT-QuIC. Background Technology
[0002] α-Synuclein (α-Syn) is a small (14 kDa) protein encoded by the SNCA gene, essentially disordered, primarily expressed at the presynaptic terminals of neurons, and involved in synaptic vesicle transport, dopamine release regulation, and synaptic plasticity. Under pathological conditions, α-Syn can misfold, forming β-sheet-rich oligomers and insoluble fibrillary aggregates. The latter are pathological markers common to many neurodegenerative diseases, collectively known as synucleinopathies. Major α-Syn-related diseases include Parkinson's disease (PD), Dementia with Lewy bodies (DLB), Multiple system atrophy (MSA), and Pure autonomic failure (PAF). These diseases exhibit overlapping symptoms clinically, making early differential diagnosis difficult, and specific blood or cerebrospinal fluid (CSF) biomarkers are lacking. α-Syn has become a highly promising diagnostic target due to its concentration and aggregation activity in biological fluids (cerebrospinal fluid, serum, plasma, exosomes).
[0003] Real-Time Quaking-Induced Conversion (RT-QuIC) is an ultrasensitive detection technique based on protein seed amplification. Initially used to detect prions, it has recently been expanded to detect amyloid proteins such as α-Syn, tau, and Aβ. RT-QuIC utilizes misfolded protein aggregates as seeds. Under continuous quaking conditions, it induces conformational changes in normally or recombinantly expressed substrate proteins (such as recombinant α-Syn) to form fibrillary aggregates. Thioflavin T (ThT) is added during the reaction; this fluorescent dye binds to the β-sheet structure, significantly increasing fluorescence intensity. The detection of the analyte is achieved by real-time monitoring of the ThT fluorescence signal.
[0004] RT-QuIC technology has the following advantages:
[0005] (1) High sensitivity: It can detect α-Syn aggregate seeds down to the picogram (pg) level. During the reaction, the seeds continuously induce the substrate to form new aggregates, which are then broken into more seeds by the mechanical collision of the glass beads, thereby amplifying the fibrillation ability of α-Syn.
[0006] (2) High specificity: It only recognizes the pathological conformation α-Syn with aggregation activity and does not cross-react with monomers or degradation fragments;
[0007] (3) Diverse sample sources: The detection matrix has been expanded from the gold standard cerebrospinal fluid to saliva, skin, serum and exosomes, which significantly improves the convenience of clinical application.
[0008] However, although α-Syn's RT-QuIC has shown some potential in the diagnosis of synucleinosis, it has not been widely adopted at present because:
[0009] (1) Poor detection stability: At present, cerebrospinal fluid is still the gold standard for detection. The concentration of α-Syn in cerebrospinal fluid is extremely low, and direct detection is prone to false negatives and insufficient sensitivity.
[0010] (2) Lack of standardization: Different laboratories use different recombinant substrates (such as full length vs. C-terminal truncation), oscillation parameters and threshold settings, resulting in poor comparability of results.
[0011] (3) Spontaneous aggregation of substrates: Recombinant substrates may exhibit non-specific aggregation, leading to false positive results.
[0012] As can be seen from the above, although RT-QuIC has certain advantages in terms of technology, it has not yet been successfully promoted as a clinical detection method for α-Syn-related diseases.
[0013] Therefore, in order to successfully leverage the advantages of RT-QuIC, it is urgent to improve the existing RT-QuIC reaction protocol and provide a stable and accurate detection method so that it is possible to use RT-QuIC to detect α-Syn-related diseases in clinical practice. Summary of the Invention
[0014] In view of this, the main objective of the present invention is to overcome the shortcomings of the current RT-QuIC detection technology and promote its application in the clinical detection of α-Syn-related diseases.
[0015] In their research on detecting α-Syn in cerebrospinal fluid using RT-QuIC technology, the inventors discovered that, in addition to defects such as poor detection stability, lack of standardization, and spontaneous substrate aggregation, many unknown interfering factors exist in cerebrospinal fluid samples, such as lipid molecules, antibodies, and metal ions. These interfering factors can bind to α-Syn seeds, interfering with the RT-QuIC reaction, significantly prolonging the lag phase of RT-QuIC detection, and significantly affecting the detection speed. Furthermore, RT-QuIC has a strict threshold dependence on the concentration of α-Syn seeds; below the critical concentration, no positive signal can be obtained, easily leading to false negatives and causing missed diagnoses in early or low-load patients.
[0016] It has been reported that TCA precipitation can be used to enrich α-Syn seeds, thereby increasing seed concentration for easier subsequent detection.
[0017] However, current TCA precipitation methods typically employ a two-step precipitation process and high TCA concentrations (Wuxian Xu, Mingyue Luan, Zhaoxia Wang, Jianwen Deng, Li Zhu. 2026: Enrichment and amplification of secreted α-synuclein from cellular model and saliva of patients with synucleinopathies. Biophysics Reports, 12(3): 137-150. DOI: 10.52601 / bpr.2025.250014). Research by the inventors has revealed that this method, especially when used on cerebrospinal fluid samples, leads to excessive aggregation of protein precipitates, forming dense clumps. Furthermore, the denatured polymer chains are highly susceptible to irreversible entanglement, severely hindering subsequent resuspension and reconstitution, impairing the resuspension, dissolution, and seed amplification activity of α-syn, and negatively impacting subsequent detection efficiency.
[0018] In response, the inventors of this invention, through research, combined the use of Triton X-100 to dissociate lipid-bound α-Syn seeds, and achieved efficient enrichment and concentration of α-Syn seeds in cerebrospinal fluid through a one-step, low-concentration TCA precipitation method. This method ensures both the enrichment and recovery efficiency of the precipitate and avoids the adverse effects of excessive aggregation on seed conformation and function, thus completing this invention.
[0019] The technical solution of the present invention is as follows:
[0020] This invention provides a method for enriching α-synuclein seeds from cerebrospinal fluid samples for RT-QuIC, comprising the following steps:
[0021] The cerebrospinal fluid sample was mixed with 0.1 v / v% to 0.5 v / v% Triton X-100 and incubated for 10 to 30 minutes. TCA was added to the incubated sample to a final concentration of 8 v / v% to 10 v / v%, and the sample was incubated on ice for 1 to 2 hours for TCA treatment. The precipitate was collected by centrifugation, rinsed to remove TCA, and resuspended to obtain enriched α-synuclein seeds.
[0022] In some implementations, the final concentration of TCA is between 8.5 v / v % and 9.5 v / v %.
[0023] In some implementations, the concentration of Triton X-100 is from 0.2 v / v% to 0.4 v / v%.
[0024] In some implementations, the TCA is mixed with the incubated sample in a single step.
[0025] This invention also provides a method for in vitro amplification of α-synuclein seeds for non-diagnostic purposes, comprising the following steps:
[0026] Cerebrospinal fluid samples were mixed with 0.1 v / v% to 0.5 v / v% Triton X-100 and incubated for 10 to 30 minutes. TCA was added to the incubated samples to a final concentration of 8 v / v% to 10 v / v%, and the samples were incubated on ice for 1 to 2 hours for TCA treatment. The precipitate was collected by centrifugation, rinsed to remove TCA, and resuspended to obtain enriched α-synuclein seeds. The enriched α-synuclein seeds were then subjected to RT-QuIC detection.
[0027] In some implementation schemes, the RT-QuIC detection system includes:
[0028] 0.1 to 0.2 mg / mL of α-synuclein, 10 to 20 μM of thioflavin T, 150 to 500 mM of NaCl, 0.0015 v / v % to 0.003 v / v % of SDS, and PBS or HEPES buffer at pH 7.4 to 8.0.
[0029] In some implementations, the temperature detected by RT-QuIC is 42°C, and the oscillation mode is oscillation for 1 minute and pause for 6 minutes.
[0030] The beneficial effects of this invention are as follows:
[0031] Thanks to the cerebrospinal fluid sample processing method of this invention, it is possible to promote RT-QuIC as a clinical detection protocol for α-Syn seeds, establishing a rapid, sensitive, and stable α-Syn cerebrospinal fluid RT-QuIC detection system. Specifically, it has the following advantages:
[0032] On the one hand, the method of the present invention significantly shortens the detection time of α-Syn seeds in cerebrospinal fluid samples by RT-QuIC. By adding Triton X-100 and a TCA treatment step with a specific final concentration, the binding of lipids to α-Syn is reduced and the α-Syn seeds are concentrated, thereby shortening the reaction lag period, significantly improving detection timeliness, and significantly increasing detection speed.
[0033] On the other hand, the method of the present invention improves the sensitivity of RT-QuIC detection of α-Syn seeds in processed cerebrospinal fluid samples. By releasing and concentrating α-Syn seeds, the present invention can detect low-concentration seed samples that are undetectable by conventional methods, and the detection sensitivity is significantly improved compared to conventional methods.
[0034] Furthermore, the method of this invention significantly improves the stability and reproducibility of RT-QuIC detection of α-Syn seeds in cerebrospinal fluid samples. By reducing the interference of lipids, this invention achieves near 100% consistency between parallel reactions, completely resolving the problem of inconsistent results in parallel replicates in conventional methods.
[0035] On the other hand, the method of the present invention is simple to operate and suitable for clinical application. The sample pretreatment step of the present invention can be seamlessly integrated with the conventional RT-QuIC operation process without the need for special equipment (only ordinary centrifuges, etc. are required). The total operation time is increased by less than 2 hours, but the total reaction time is significantly shortened, and the overall cost is not significantly increased. Attached Figure Description
[0036] Figure 1 The figure shows the results of α-Syn recombinant protein expression, purification, and immunoblotting verification.
[0037] Figure 2 The image shows the RT-QuIC results for the α-Syn recombinant protein.
[0038] Figure 3 The figure shows the results of Example 3 verifying the inhibitory effect of cerebrospinal fluid on RT-QuIC detection.
[0039] Figure 4 The figure shows the experimental results of Example 4, which verify that the RT-QuIC reaction depends on the seed concentration.
[0040] Figure 5 The figure shows the experimental results of Example 5, which verifies the threshold effect of RT-QuIC reaction in detecting brain tissue lysate.
[0041] Figure 6The images show the SDS-PAGE and BCA results for the experimental and control groups in Example 6. M represents the protein molecular weight marker; Lane 1 is the initial α-Syn protein, 4 μg; Lane 2 is the α-Syn protein recovered by one-step TCA precipitation (initial 4 μg); Lane 3 is the initial α-Syn protein, 2 μg; and Lane 4 is the α-Syn protein recovered by two-step TCA precipitation (initial 2 μg).
[0042] Figure 7 The figure shows a comparison of RT-QuIC detection results with different TCA preprocessing methods.
[0043] Figure 8 Figure showing the experimental results of using TCA-concentrated brain tissue samples for RT-QuIC detection.
[0044] Figure 9 Figure showing experimental results of TCA-treated clinical cerebrospinal fluid samples for RT-QuIC detection.
[0045] Figure 10 A comparison of the results of seeds obtained with different amounts of TCA for RT-QuIC detection. Detailed Implementation
[0046] The technical solution of the present invention will be clearly and completely described below with reference to specific embodiments. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of them. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0047] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood in the art to which this invention pertains. The following definitions supplement those in the art and relate to this application, but are not extrapolated to any relevant or unrelated circumstances, such as any conventionally used patent or application. While any methods and materials similar to or equivalent to those described herein may be used in practical testing, the materials and methods described herein are preferred. Therefore, the terminology used herein is intended to describe specific embodiments only and is not intended to limit the invention.
[0048] In this document, the terms “including,” “comprising,” and “having” are open-ended descriptions that include the specified steps described, as well as other steps that do not materially affect them, and are optional and not excluded.
[0049] In order to improve the detection efficiency of α-Syn seeds in cerebrospinal fluid, the inventors of this invention conducted a series of studies and improved the existing detection methods, thereby completing this invention.
[0050] The specific technical solution of the present invention is as follows:
[0051] This invention provides a method for enriching α-synuclein seeds from cerebrospinal fluid samples for RT-QuIC, comprising the following steps:
[0052] The cerebrospinal fluid sample was mixed with 0.1 v / v% to 0.5 v / v% Triton X-100 and incubated for 10 to 30 minutes. TCA was added to the incubated sample to a final concentration of 8 v / v% to 10 v / v%, and the sample was incubated on ice for 1 to 2 hours for TCA treatment. The precipitate was collected by centrifugation, rinsed to remove TCA, and resuspended to obtain enriched α-synuclein seeds.
[0053] In this invention, the final concentration of TCA used is 8 v / v % to 10 v / v %. Most existing TCA precipitation methods use higher final TCA concentrations (e.g., 15 v / v %, 20 v / v %, or higher) to completely precipitate α-Syn in the sample, improving sedimentation rate and detection efficiency. However, the inventors of this invention unexpectedly discovered in their research that even using a lower concentration of TCA achieved good results for cerebrospinal fluid samples, particularly shortening the hysteresis period and improving seed activity in RT-QuIC detection of cerebrospinal fluid samples.
[0054] In the method of this invention, the final concentration of TCA can be 8 v / v%, 8.1 v / v%, 8.2 v / v%, 8.3 v / v%, 8.4 v / v%, 8.5 v / v%, 8.6 v / v%, 8.7 v / v%, 8.8 v / v%, 8.9 v / v%, 9 v / v%, 9.1 v / v%, 9.2 v / v%, 9.3 v / v%, 9.4 v / v%, 9.5 v / v%, 9.6 v / v%, 9.7 v / v%, 9.8 v / v%, 9.9 v / v%, or 10 v / v. In some specific embodiments, the final concentration of TCA is from 8.5 v / v% to 9.5 v / v%.
[0055] In the method of this invention, the concentration of Triton X-100 is from 0.1 v / v% to 0.5 v / v%. For example, the concentration of Triton X-100 can be 0.1 v / v%, 0.2 v / v%, 0.3 v / v%, 0.4 v / v%, or 0.5 v / v. In some specific embodiments, the concentration of Triton X-100 is from 0.2 v / v% to 0.4 v / v.
[0056] In some implementations, TCA is mixed with the incubated sample solution in a single step.
[0057] In a specific implementation, the TCA process occurs after the Triton X-100 process, preferably immediately following the Triton X-100 process.
[0058] In a specific implementation, mixing TCA with the sample solution (sample or mixture containing the sample) in a single operation means mixing TCA with the sample solution in one operation so that the final concentration of TCA in the resulting mixture is 8 v / v% to 10 v / v%. In other words, during the mixing of TCA with the sample solution to obtain a mixture with a final concentration of 8 v / v% to 10 v / v%, there are no incubation steps (such incubation steps may be 1 min to 10 min), centrifugation steps, or settling steps (such settling steps may be 1 min to 10 min).
[0059] Existing methods typically employ a two-step TCA precipitation approach. For example, a rapid precipitation is first performed using a final concentration of 20 v / v % TCA (e.g., 250 μL of 100% TCA per mL of sample), followed by the addition of more TCA to a final concentration of approximately 16.6 v / v % for further precipitation. This two-step precipitation strategy aims to enhance precipitation efficiency through stepwise acid addition, particularly beneficial for the recovery of small molecular weight proteins. However, while the two-step precipitation method can improve the sedimentation rate of small proteins to some extent, it is not optimal for α-syn seeds (i.e., high molecular weight polymers formed by the aggregation of multiple monomers). This is because the molecular weight of the seeds is much larger than that of the monomers (15 kDa), and their precipitation behavior is not sensitive to TCA concentration. Conversely, higher concentrations of TCA can lead to excessive aggregation of protein precipitates, forming dense clumps, and the denatured polymer chains are prone to irreversible entanglement, severely hindering subsequent resuspension and resolution. In the method of this invention, the inventors unexpectedly discovered that for α-Syn seeds in cerebrospinal fluid samples, low-concentration single-step TCA precipitation is actually more suitable for subsequent RT-QuIC detection.
[0060] In some implementations, the incubation time for Triton X-100 mixed with the sample is 10 to 30 minutes, for example, 10 minutes, 15 minutes, 20 minutes, 25 minutes or 30 minutes.
[0061] In some implementations, after adding TCA, it can be mixed with the sample using any suitable method. For example, it can be mixed by vortexing, while maintaining the protein structure during the vortexing process.
[0062] In some implementations, the sample is incubated with TCA for 1 to 2 hours, for example, 1 hour, 1.5 hours or 2 hours.
[0063] In an embodiment of the present invention, the sample may be a cerebrospinal fluid sample or a lysate sample of brain tissue.
[0064] In embodiments of the present invention, the precipitate can be collected using any suitable centrifugation conditions. For example, centrifugation conditions can be 15,000 rpm for 10 to 20 minutes.
[0065] In embodiments of the invention, the precipitate can be washed with any suitable solvent to remove TCA. For example, the solvent could be acetone.
[0066] In embodiments of the present invention, the precipitate can be resuspended using any suitable solvent. For example, it can be resuspended using a buffer solution (50 mM Tris, 0.1% Triton X-100, 150 mM NaCl).
[0067] In embodiments of the present invention, the incubation process is carried out under low temperature conditions (e.g., on ice or at 4°C).
[0068] In embodiments of the present invention, the reagents added to the system (e.g., TCA, solvents for removing TCA, buffer solutions for resuspending precipitates) are all pre-cooled.
[0069] This invention also provides a method for in vitro amplification of α-synuclein seeds for non-diagnostic purposes, comprising the following steps:
[0070] Cerebrospinal fluid samples were mixed with 0.1 v / v% to 0.5 v / v% Triton X-100 and incubated for 10 to 30 minutes. TCA was added to the incubated samples to a final concentration of 8 v / v% to 10 v / v%, and the samples were incubated on ice for 1 to 2 hours for TCA treatment. The precipitate was collected by centrifugation, rinsed to remove TCA, and resuspended to obtain enriched α-synuclein seeds. The enriched α-synuclein seeds were then subjected to RT-QuIC detection.
[0071] In some implementation schemes, the RT-QuIC detection system includes:
[0072] 0.1 to 0.2 mg / mL α-synuclein, 10 to 20 μM thioflavone T, 150 to 500 mM NaCl, 0.0015 v / v % to 0.003 v / v % SDS, and PBS or HEPES buffer at pH 7.4 to 8.0; RT-QuIC assay was performed at 42 °C with a shaking mode of 1 minute shaking followed by a 6-minute pause.
[0073] In some implementations, the RT-QuIC detection system may also include glass beads (0.8 mm, 3-6 beads per well) to enhance the oscillation-induced effect.
[0074] The following describes preferred embodiments of the present invention, but the scope of protection of the present invention is not limited to these preferred embodiments. It should be noted that any modifications and improvements made by those skilled in the art based on this inventive concept are within the scope of protection of the present invention. All reagents used, unless otherwise specified, are commercially available conventional products.
[0075] Example 1: Expression and purification of α-Syn recombinant protein
[0076] Expression of α-Syn recombinant protein:
[0077] (1) α-Syn was constructed into the pET28a plasmid with a his tag at the C-terminus;
[0078] (2) The constructed pET28a-α-Syn plasmid was transformed into E. coli BL21(DE3);
[0079] (3) The transformed Escherichia coli were spread on LB culture plates and incubated overnight at 37°C;
[0080] (4) Pick a single colony from the overnight LB agar plate and inoculate it into a 50 mL pre-culture shake flask. Incubate overnight at 37°C and 220 rpm until the OD value is reached. 600 ≈3;
[0081] (5) Using aseptic technique, transfer the cells to a 50 mL conical centrifuge tube and centrifuge at 3000 g for 5 minutes at 4 °C to form a cell pellet. Discard the supernatant and wash the pellet with approximately 20 mL of pre-cooled washing buffer;
[0082] (6) Resuspend the cells in the conical tube with growth medium, and transfer equal amounts of cells to 2L shake flasks. Add 500mL of growth medium to each flask and incubate at 37℃ and 220rpm with shaking until OD. 600 The expression level reached approximately 0.8–1.0. Then, 1 mL of IPTG stock solution was added to induce α-Syn overexpression. The mixture was incubated at 18°C with shaking at 200 rpm.
[0083] (7) After overnight culture (approximately 18 hours after induction), collect the cells and combine them into a 1L centrifuge flask. Centrifuge at 2500g for 10 minutes at 4°C. Discard the supernatant and wash the cell pellet with washing buffer to remove residual growth medium components;
[0084] (8) The obtained cell pellet can be frozen at -80℃ for later use.
[0085] Purification of α-Syn recombinant protein:
[0086] (1) Take out the Escherichia coli cells expressing His tag fusion protein from -80℃ and thaw them on ice.
[0087] (2) Add 10 mL of lysis buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM PMSF, lysozyme optional) per gram of wet bacteria, resuspend the bacterial cells, and sonicate on ice (30% power, 3 seconds of sonication, 5 seconds of interval, total time 10 to 15 minutes).
[0088] (3) Centrifuge at 15000g for 2 minutes at 4℃ and collect the supernatant. Filter the supernatant through a 0.45μm filter membrane for later use.
[0089] (4) Use Ni-NTA pre-installed columns to connect to ÄKTA or gravity column systems.
[0090] (5) Equilibration: Equilibrate the column with 5 column volumes of equilibration buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM imidazole).
[0091] (6) Loading: Load the filtered supernatant at a flow rate of 1 mL / min (for gravity columns, use the natural flow rate).
[0092] (7) Washing: Wash away non-specific binding proteins with 10 to 15 column volumes of washing buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 20-40 mM imidazole) until the UV280 baseline is stable.
[0093] (8) Elution: Elute in fractions with elution buffer (50mM Tris-HCl pH 8.0, 300mM NaCl, 250-500mM imidazole) and collect each fraction (1 mL per tube).
[0094] (9) Detection: SDS-PAGE was used to identify fragments containing the target protein and then pooled.
[0095] (10) Select Superdex 200 Increase 10 / 300 GL or select a suitable gel filter column according to the protein molecular weight.
[0096] (11) Equilibration: Equilibrate the column with gel filtration buffer (50mM Tris-HCl pH 8.0, 150mM NaCl, or PBS) to a volume of at least 1.5 column volume.
[0097] (12) Sample concentration: The combined solution eluted from the nickel column is concentrated to a volume ≤500μL using an ultrafiltration tube.
[0098] (13) Sample loading and elution: Load the sample at a flow rate of 0.5 to 1.0 mL / min, collect the fraction (0.5 mL per tube), and monitor UV280.
[0099] (14) Analysis: SDS-PAGE identifies the fractions corresponding to the monomer peaks and merges the fractions with the highest purity.
[0100] (15) Concentration and preservation: Concentrate the final sample to the required concentration, dispense it, freeze it in liquid nitrogen, and store it at -80℃.
[0101] The concentrated α-Syn sample was prepared and subjected to SDS-PAGE and Western blot. The results are as follows: Figure 1 As shown in the figure, the electrophoretic band of the α-Syn recombinant protein is approximately 20 kDa, and the α-Syn recombinant protein can be recognized by a commercially available α-Syn antibody (10842-1-AP, Proteintech).
[0102] Example 2: α-Syn recombinant protein successfully used for RT-QuIC detection
[0103] To test whether the obtained α-Syn recombinant protein has substrate activity and can form fibrils under α-Syn seed induction, an RT-QuIC reaction was performed according to the following steps:
[0104] (1) On a black 96-well plate (such as Nunc) ™ Fill the plate with 0.8 mm glass beads (4 beads per hole) and pre-cool the plate on ice for later use.
[0105] (2) Dilute the components including ThT, the α-Syn recombinant protein obtained in Example 1 (as a reaction substrate) and the commercial seed (activated seed, ab218819) for later use.
[0106] (3) Prepare the RT-QuIC reaction system according to the table below:
[0107]
[0108] (4) Preheat the BMG FLUOstar Omega microplate reader to 42°C.
[0109] (5) Set the oscillation parameters: 300 rpm, dual-track mode, oscillate for 1 minute, rest for 6 minutes, and record ThT fluorescence every 7 minutes.
[0110] (6) Configure fluorescence detection parameters: excitation / emission wavelength = 450 / 480 nm, and optimize the gain to 80% to 90% of the positive control saturation.
[0111] (7) Seal the 96-well plate containing the reaction system with a transparent sealing film and incubate the reaction in a BMG FLUOstar Omega microplate reader.
[0112] Test results as follows Figure 2 As shown, the α-Syn recombinant protein reached a stable plateau after about 5.5 hours.
[0113] Example 3: Verification of the inhibitory effect of cerebrospinal fluid on RT-QuIC
[0114] Currently, the gold standard for RT-QuIC detection of α-Syn still uses cerebrospinal fluid (CSF) samples. However, CSF may contain factors that inhibit the RT-QuIC response. To verify this hypothesis, RT-QuIC detection was performed with or without CSF (CSF obtained from individuals with clinical encephalitis, collected after the subjects signed informed consent, and containing no α-Syn seeds) added to the reaction systems for positive seeds and α-Syn (see below for specific reaction systems).
[0115] Reaction system without cerebrospinal fluid:
[0116]
[0117] Reaction system with added cerebrospinal fluid:
[0118]
[0119] The prepared reaction system was tested using the same procedure as described above.
[0120] The results are as follows Figure 3 As shown, although the peak time points are basically the same after the addition of cerebrospinal fluid, the time for the reaction curve to reach the plateau phase is delayed by approximately 30 hours. This indicates the presence of inhibitory factors for the RT-QuIC reaction in cerebrospinal fluid; removing these inhibitory factors would improve the timeliness of the detection.
[0121] Example 4: Dependence of α-Syn RT-QuIC reaction on seed concentration and threshold effect
[0122] The RT-QuIC detection of α-Syn degeneration is a highly concentration-dependent reaction. To verify this idea, commercially available α-Syn protein seeds were used directly, serially diluted, and then used as seeds for the RT-QuIC reaction. The specific reaction system is shown in the table below.
[0123]
[0124] The prepared reaction system was tested using the same procedure as described above.
[0125] The results are as follows Figure 4 As shown, excluding the influence of accidental factors, the time for the RT-QuIC reaction to reach the plateau phase gradually decreases with decreasing seed concentration. When the seed amount drops to 14 fg, the reaction fails to produce a peak, indicating that the detection system exhibits a threshold effect, with the detection limit approximately between 14 and 140 fg.
[0126] Example 5: Dilution dependence and threshold effect of PD mouse brain tissue lysate in α-Syn RT-QuIC assay
[0127] The experimental results of Example 4 demonstrate that the RT-QuIC detection of α-Syn exhibits a highly concentration-dependent response. Further, this phenomenon was verified using biological samples, specifically PD model mice (A53T mice). The specific steps are as follows:
[0128] Because collecting cerebrospinal fluid samples from mice is difficult and involves significant individual variability, mouse brain tissue fluid was used in mouse experiments to provide a sufficient and homogeneous sample in order to better verify the ability of RT-QuIC to detect α-Syn in the sample.
[0129] Brains were rapidly harvested from 12-week-old A53T mice after sacrifice, rinsed with pre-chilled PBS to remove blood, and placed in pre-chilled 1.5 mL or 2 mL centrifuge tubes. RIPA lysis buffer containing protease inhibitors was added at a ratio of 1:10 (w / v), homogenized on ice, and incubated on ice for 30 minutes. The mixture was then centrifuged at 15000 g for 20 minutes at 4°C. The supernatant was aliquoted and stored at -80°C for later use. This supernatant was used as seed for RT-QuIC detection; the specific reaction system is shown in the table below.
[0130]
[0131] The prepared reaction system was tested using the same procedure as described above.
[0132] The results are as follows Figure 5 As shown, the time it takes for the RT-QuIC reaction to reach the plateau phase gradually increases with the dilution factor of the brain tissue lysis fluid. When the dilution factor reaches 100,000 times, the reaction fails to produce a peak and can be judged as negative, indicating that the detection system has a significant threshold effect.
[0133] Example 6: Sample processing using the method of the present invention
[0134] The content of α-Syn seed protein in cerebrospinal fluid is low, and its concentration varies significantly among individuals, posing challenges to the standardization and stability of detection. False negatives or poor reproducibility are common, thus affecting the accurate assessment and treatment of patients' conditions. Therefore, this invention establishes a concentration pretreatment method based on TCA precipitation.
[0135] The sample processing method of this invention uses a one-step TCA precipitation, while existing reports use a two-step precipitation. To evaluate the concentration efficiency of different TCA precipitation methods for α-Syn protein seeds, a simulation experiment was conducted for comparison. The one-step precipitation method was used as the experimental group, and the two-step precipitation method was used as the control group. The specific processing methods are as follows:
[0136] The experimental group's sample consisted of 50 μg of α-Syn recombinant protein. The TCA treatment procedure was as follows: the sample was diluted to 900 μL, 100 μL of 100% TCA was added, and the sample was treated on ice for 1 hour. The precipitate was collected by centrifugation at 15000g for 10 minutes at 4°C. 500 μL of acetone pre-chilled in an ice bath was added to wash away residual TCA. The sample was briefly vortexed, centrifuged at 17000g for 5 minutes at 4°C, and the supernatant was discarded. This process was repeated once. The precipitate was then air-dried in a vacuum evaporator for 2-5 minutes and resuspended in PBS or 1×SDS loading buffer.
[0137] The control group had the same sample as the experimental group, except that the TCA treatment steps were as follows: the sample was diluted to 800 μL, 200 μL of 100% TCA was added and the sample was incubated on ice for 10 minutes, then 10% TCA was added at a ratio of 1:2 (500 μL of 10% TCA was added to 1 mL of sample), and the sample was incubated on ice for another 20 minutes. The precipitate was collected by centrifugation at 15000g for 10 minutes at 4°C, 500 μL of acetone pre-chilled in an ice bath was added to wash away residual TCA, the sample was briefly vortexed, and centrifuged at 17000g for 5 minutes at 4°C. The supernatant was discarded, and the process was repeated once. The precipitate was then air-dried in a vacuum evaporator for 2-5 minutes and resuspended in PBS or 1×SDS loading buffer.
[0138] Then, SDS-PAGE and BCA methods were used to detect the proteins obtained from the experimental group and the control group. The specific detection methods are as follows:
[0139] BCA method for quantifying total protein recovery:
[0140] (1) Preparation of standard curve: The BSA standard (2 mg / mL) in the BCA kit is serially diluted with PBS or a reconstitution solution matched with the sample (concentration gradient is set as: 500, 400, 300, 200, 100, 50, 25, 0 μg / mL).
[0141] (2) Sample preparation: Take 20 μL of the original sample (before TCA treatment) and the sample reconstituted after one-step / two-step TCA precipitation, and add them to a 96-well plate. Add 200 μL of BCA working solution to each well and shake to mix for 30 seconds.
[0142] (3) Incubation and reading: Incubate at 37°C in the dark for 30 minutes, cool to room temperature, and then measure the absorbance at 562 nm using an enzyme-linked immunosorbent assay (ELISA) reader.
[0143] (4) Calculate the concentration: based on the OD of the BSA standard. 562 Plot a four-parameter or linear standard curve using the values of the sample's OD. 562 Substitute the data into the curve to calculate the original protein concentration (Coriginal) and the protein concentration after reconstitution (Creconstitute).
[0144] Quantitative analysis using SDS-PAGE combined with grayscale scanning:
[0145] (1) Normalized loading: To ensure comparability, take equal volumes of the original sample and the sample after precipitation and reconstitution (e.g., 5 μL each, or 4 μg of total protein each), add equal volumes of SDS loading buffer, and boil for denaturation for 10 minutes.
[0146] (2) Electrophoresis and staining: SDS-PAGE electrophoresis was performed at constant voltage and stopped when bromophenol blue reached the edge of the gel bottom. After peeling off the gel, it was placed in Coomassie Brilliant Blue R-250 staining solution and stained with shaking for 1 hour, and then destained until the background was clear.
[0147] (3) Image acquisition and grayscale analysis: Images were taken using a gel imaging system and saved in TIFF format. ImageJ software was used to delineate the grayscale value (integrated density) of the total protein in the target protein band region.
[0148] (4) Correction process: Divide the gray value of the target protein in each lane by its corresponding loading volume correction coefficient (if the loading amounts are not absolutely equal, they need to be divided by the total protein loading amount for normalization).
[0149] (5) Calculation: Protein recovery rate equals TCA-treated lane gray value / original sample gray value.
[0150] Experimental results are as follows Figure 6 As shown, SDS-PAGE electrophoresis results indicate that the recovery rate of TCA precipitation using the one-step method is approximately 90%, while the recovery rate using the two-step method reaches 96%. However, the opposite is true for BCA detection using PBS resuspension: the recovery rate of TCA precipitation using the one-step method is approximately 88%, while the recovery rate using the two-step method is only 70%. In other words, although the two-step TCA treatment yields more protein, its solubility is relatively poor, which may be detrimental to subsequent RT-QuIC detection.
[0151] Example 7 Comparison of RT-QuIC detection results with different TCA pretreatment methods
[0152] The experimental results in Example 6 confirm that although the two-step TCA precipitation can improve the protein recovery rate, the solubility of the precipitate is significantly poor, and the effect of this treatment on the activity of α-Syn seeds is still unclear.
[0153] To systematically evaluate the effects of different TCA precipitation strategies on the viability of α-Syn seeds and determine the optimal treatment scheme suitable for these seeds, this embodiment diluted commercial α-Syn seeds to a specified concentration and recovered them using one-step and two-step TCA precipitation methods. The experimental procedures for the one-step and two-step methods were similar to those in Example 6, except that in Example 6, both the experimental and control groups used 50 μg of recombinant α-Syn protein, while in this embodiment, both the experimental and control groups used 40 μg of recombinant α-Syn protein and 10 μg of commercial α-Syn seed protein. The specific treatment methods are as follows:
[0154] In the experimental group, 40 μg of α-Syn recombinant protein and 10 μg of α-Syn commercial seed protein were diluted to 900 μL, 100 μL of 100% TCA was added, and the mixture was treated on ice for 1 hour. The precipitate was collected by centrifugation at 15000g for 10 minutes at 4°C. 500 μL of acetone pre-chilled in an ice bath was added to wash away residual TCA. The mixture was briefly vortexed and centrifuged at 17000g for 5 minutes at 4°C. The supernatant was discarded, and the process was repeated once. The precipitate was air-dried in a vacuum evaporator for 2-5 minutes and then resuspended in PBS or 1×SDS loading buffer.
[0155] In the control group, 40 μg of α-Syn recombinant protein and 10 μg of α-Syn commercial seed protein were diluted to 800 μL. 200 μL of 100% TCA was added and the mixture was treated on ice for 10 minutes. Then, 10% TCA was added at a ratio of 1:2 (500 μL of 10% TCA was added to 1 mL of sample), and the mixture was treated on ice for another 20 minutes. The precipitate was collected by centrifugation at 15000g for 10 minutes at 4°C. 500 μL of acetone pre-chilled in an ice bath was added to wash away residual TCA. The mixture was briefly vortexed and centrifuged at 17000g for 5 minutes at 4°C. The supernatant was discarded, and the process was repeated once. The precipitate was air-dried in a vacuum evaporator for 2-5 minutes and then resuspended in PBS or 1×SDS loading buffer.
[0156] Subsequently, the resuspended solutions of the experimental and control groups were used as seeds for RT-QuIC detection. The amplification activity of the seeds under the two treatments was detected by the RT-QuIC reaction system. The reaction peak time (T50) was used as the main indicator to evaluate the degree of change of seed activity by each precipitation method.
[0157] The specific reaction system is shown in the table below.
[0158]
[0159] The prepared reaction system was tested using the same procedure as described above.
[0160] The results are as follows Figure 7 As shown, the peak time of the two-step method is delayed compared to the one-step method, and the maximum reaction rate is significantly smaller, suggesting that the activity of α-Syn seeds or the concentration of soluble seeds is reduced in the two-step method.
[0161] Therefore, the results of Examples 6 and 7 show that the one-step TCA pretreatment can balance the recovery rate of seed protein and the preservation of seed activity, making it the best choice for pretreatment.
[0162] Example 8: TCA-concentrated brain tissue samples used for RT-QuIC detection
[0163] As shown in Examples 4 and 5, RT-QuIC detection has certain limitations, requiring high seed concentration. Furthermore, significant differences in seed concentration among individual patients pose challenges to the sensitivity and stability of the detection, easily leading to false negatives or poor repeatability. In addition, as shown in Example 3, cerebrospinal fluid samples themselves contain interfering factors that inhibit the RT-QuIC response.
[0164] To overcome the above problems, this invention introduces Triton X-100 and TCA pretreatment steps on the basis of conventional RT-QuIC detection.
[0165] Specifically, the sample processing steps of the present invention are as follows:
[0166] (1) Collect the sample (brain tissue lysate) into a pre-cooled 1.5 mL microcentrifuge tube.
[0167] (2) Centrifuge at 1000g for 5 minutes at 4°C to remove cell debris, and transfer the clear supernatant to a new microcentrifuge tube.
[0168] (3) Add Triton X-100 to the supernatant to a final concentration of 0.3% and incubate on ice for 30 minutes.
[0169] (4) Add 100% TCA pre-cooled in an ice bath to the supernatant at a volume ratio of 1:9 (e.g., add 100 μL of 100% TCA per 900 μL of sample).
[0170] (5) Gently vortex for 10 seconds and incubate on ice for 1 hour to precipitate the protein.
[0171] (6) Centrifuge at 4°C and 15000g for 10 minutes, carefully discard the supernatant, and do not disturb the precipitate.
[0172] (7) Add 500 μL of acetone pre-cooled in an ice bath to wash away residual TCA. Vortex briefly, centrifuge at 17000 g for 5 minutes at 4°C, discard the supernatant, and repeat once.
[0173] (8) Dry the precipitated air with a vacuum evaporator for 2-5 minutes.
[0174] (9) Resuspend the precipitate in an appropriate volume of PBS.
[0175] Based on the above method, the lysate samples of PD model mouse brain tissue were pretreated. Specifically, 1 mL of PD mouse brain tissue lysate diluted 100,000 times was processed according to the above sample treatment method, and the resulting TCA precipitate was resuspended in 50 μL PBS.
[0176] Tissue lysis buffer diluted 100,000 times and TCA precipitate resuspension were subjected to RT-QuIC detection. The specific reaction system is shown in the table below.
[0177]
[0178] The prepared reaction system was tested using the same procedure as described above.
[0179] The results are as follows Figure 8 As shown, the brain tissue lysate diluted 100,000 times failed to produce a peak and could be considered negative. However, the resuspended solution of the diluted solution after treatment with Triton X-100 and TCA was able to produce a peak and reach a plateau in the RT-QuIC reaction and could be considered positive. This indicates that the sample pretreatment of the present invention can indeed improve the sensitivity of RT-QuIC detection of biological samples.
[0180] Example 9: TCA-treated clinical cerebrospinal fluid samples for RT-QuIC detection
[0181] The initiation of RT-QuIC detection depends on the seed concentration reaching a critical nucleation threshold (Example 8). Below this threshold, the signal cannot amplify, easily leading to false negatives. However, the seed load in clinical cerebrospinal fluid samples varies greatly among individuals, resulting in poor reproducibility of direct detection. To address this, this invention introduces a TCA precipitation and concentration step before RT-QuIC. By adjusting the ratio of the initial loading volume to the final resuspension volume, the absolute seed concentration can be increased several times over. Simultaneously, Triton X-100 treatment is used to eliminate the vesicle shielding effect and reduce the background of high-abundance proteins, thereby ensuring the detection rate of low-load samples and well-to-well parallelism.
[0182] Specifically, the sample processing steps of the present invention are as follows:
[0183] (1) Collect the sample (cerebrospinal fluid) into a pre-cooled 1.5 mL microcentrifuge tube.
[0184] (2) Centrifuge at 1000g for 5 minutes at 4°C to remove cell debris, and transfer the clear supernatant to a new microcentrifuge tube.
[0185] (3) Add Triton X-100 to the supernatant to a final concentration of 0.3% and incubate on ice for 30 minutes.
[0186] (4) Add 100% TCA pre-cooled in an ice bath to the supernatant at a volume ratio of 1:9 (e.g., add 100 μL of 100% TCA per 900 μL of sample).
[0187] (5) Gently vortex for 10 seconds and incubate on ice for 1 hour to precipitate the protein.
[0188] (6) Centrifuge at 4°C and 15000g for 10 minutes, carefully discard the supernatant, and do not disturb the precipitate.
[0189] (7) Add 500 μL of acetone pre-cooled in an ice bath to wash away residual TCA. Vortex briefly, centrifuge at 17000 g for 5 minutes at 4°C, discard the supernatant, and repeat once.
[0190] (8) Dry the precipitated air with a vacuum evaporator for 2-5 minutes.
[0191] (9) Resuspend the precipitate in an appropriate volume of PBS.
[0192] Based on the above method, cerebrospinal fluid samples from two clinical PD patients (from the Parkinson's Disease and Movement Disorders Ward, Department of Neurology, Xuanwu Hospital, Capital Medical University, clinically diagnosed with Parkinson's disease according to the MDS 2015 diagnostic criteria, denoted as Patient A and Patient B, respectively) were pretreated. Specifically, 1 mL of cerebrospinal fluid was processed according to the above sample processing method, and the resulting TCA precipitate was resuspended in 50 μL of PBS.
[0193] The original cerebrospinal fluid and the TCA precipitate resuspension were subjected to RT-QuIC detection. The specific reaction system is shown in the table below.
[0194]
[0195] The prepared reaction system was tested using the same procedure as described above.
[0196] The results show (e.g.) Figure 9In two clinically diagnosed Parkinson's disease patients, the cerebrospinal fluid samples failed to elicit an RT-QuIC reaction (fluorescence signal did not reach the threshold), resulting in negative results. However, after treatment with Triton X-100 and TCA, the resuspended precipitates showed typical positive amplification curves (significantly shortened peak time and fluorescence intensity reaching the plateau phase). This data confirms that the pretreatment method of this invention successfully avoids the risk of false negatives in raw sample detection by effectively removing soluble interfering substances and enriching α-Syn seeds. The positive detection results after treatment were highly consistent with the patients' clinical diagnoses, demonstrating that this method can improve the detection sensitivity of extremely low abundance pathological seeds to a clinically identifiable level.
[0197] Example 10: TCA gradient precipitation seed for RT-QuIC detection
[0198] Based on the establishment that the overall operational convenience and detection efficiency of the one-step TCA precipitation method combined with RT-QuIC detection are superior to the traditional two-step method, this invention further optimized and screened the final concentration of TCA, the core process parameter in the one-step method (experimental groups in Examples 6 and 7).
[0199] In this embodiment, the experimental process is similar to that of the experimental groups in Examples 6 and 7, using a one-step method for seed concentration. The only difference is the final concentration of TCA added in each group. In Examples 6 and 7, the final concentration of TCA was 10%, while in this embodiment, two additional groups were added with final concentrations of 16% and 20%, respectively. Similar to the experimental group in Example 7, this embodiment also uses 40 μg of α-Syn recombinant protein and 10 μg of α-Syn commercial seed protein for treatment.
[0200] The treated resuspension was used as a seed for RT-QuIC detection. The specific reaction system is shown in the table below.
[0201]
[0202] The prepared reaction system was tested using the same procedure as described above.
[0203] The results are as follows Figure 10As shown, when 10% (w / v) TCA was used for seed protein precipitation, the subsequent RT-QuIC reaction exhibited superior performance. However, when the final TCA concentration was increased to 16% and 20%, the reaction lag time was significantly prolonged compared to the 10% concentration group. This phenomenon suggests that excessively high TCA concentrations may have caused excessive aggregation of seed proteins or co-precipitated inhibitory components in the reaction system, thus sacrificing the detection efficiency and reaction kinetics of RT-QuIC to some extent. In other words, a higher TCA concentration in the precipitation system is not necessarily better. When 10% TCA was used for seed protein precipitation, the subsequent RT-QuIC reaction exhibited superior performance—a shorter lag time; while when the TCA concentration was increased to 16% and 20%, the reaction lag time was significantly prolonged compared to the 10% concentration group.
[0204] In summary, this invention confirms that using 8%-10% TCA for precipitation and concentration in the method of this invention can achieve the optimal balance between detection sensitivity and reaction rate.
[0205] The above description is merely a preferred embodiment of the present invention and is not intended to limit the scope of protection of the present invention.
Claims
1. A method for enriching α-synuclein seeds from cerebrospinal fluid samples for RT-QuIC, characterized in that, The method includes the following steps: The cerebrospinal fluid sample was mixed with 0.1 v / v% to 0.5 v / v% Triton X-100 and incubated for 10 to 30 minutes. Add TCA to the incubated sample at a final concentration of 8 v / v % to 10 v / v % and incubate on ice for 1 to 2 hours for TCA treatment. Centrifuge to collect the precipitate. Rinsing and settling removes TCA. The precipitate was resuspended to obtain enriched α-synuclein seeds.
2. The method according to claim 1, characterized in that, The final concentration of TCA ranges from 8.5 v / v % to 9.5 v / v %.
3. The method according to claim 1, characterized in that, The concentration of Triton X-100 is from 0.2 v / v% to 0.4 v / v%.
4. The method according to any one of claims 1 to 3, characterized in that, The method involves only one TCA process.
5. A method for in vitro amplification of α-synuclein seeds for non-diagnostic purposes, characterized in that, The method includes the following steps: After mixing the cerebrospinal fluid sample with 0.1 v / v% to 0.5 v / v% Triton X-100, incubate for 10 to 30 minutes. Add TCA to the incubated sample at a final concentration of 8 v / v % to 10 v / v % and incubate on ice for 1 to 2 hours for TCA treatment. Centrifuge to collect the precipitate. Rinsing and settling removes TCA. The precipitate was resuspended to obtain enriched α-synuclein seeds; The enriched α-synuclein seeds were analyzed by RT-QuIC.
6. The method according to claim 5, characterized in that, The final concentration of TCA ranges from 8.5 v / v % to 9.5 v / v %.
7. The method according to claim 5, characterized in that, The concentration of Triton X-100 is from 0.2 v / v% to 0.4 v / v%.
8. The method according to any one of claims 5 to 7, characterized in that, The method involves only one TCA process.
9. The method according to any one of claims 5 to 7, characterized in that, The RT-QuIC detection system includes: 0.1 to 0.2 mg / mL of α-synuclein, 10 to 20 μM of thioflavin T, 150 to 500 mM of NaCl, 0.0015 v / v% to 0.003 v / v% of SDS, and PBS or HEPES buffer at pH 7.4 to 8.0.
